Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22


Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments.

Jaki T, Vasileiou D.

Stat Med. 2017 Feb 20;36(4):563-580. doi: 10.1002/sim.7159. Epub 2016 Nov 2.


A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.

Saito I, Azuma K, Kakikawa T, Oshima N, Hanson ME, Tershakovec AM.

Lipids Health Dis. 2015 May 1;14:40. doi: 10.1186/s12944-015-0036-z.


Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy.

Lynch JT, Cooke CE, Rosen J, Gandhi S, Bullano MF.

Am Health Drug Benefits. 2010 Sep;3(5):340-9.


Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy.

Lowe RN, Marrs JC, Saseen JJ.

Ther Adv Drug Saf. 2013 Feb;4(1):9-17. doi: 10.1177/2042098612474293.


Is combined lipid-regulating therapy safe and feasible for the very old patients with mixed dyslipidemia?

Zou X, Si QJ.

J Geriatr Cardiol. 2013 Dec;10(4):349-54. doi: 10.3969/j.issn.1671-5411.2013.04.014.


Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.


Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.

Abramson BL, Benlian P, Hanson ME, Lin J, Shah A, Tershakovec AM.

Lipids Health Dis. 2011 Aug 22;10:146. doi: 10.1186/1476-511X-10-146.


Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients.

Oh MS, Min YJ, Kwon JE, Cho EJ, Kim JE, Lee WS, Lee KJ, Kim SW, Kim TH, Kim CJ, Ryu WS.

Korean Circ J. 2011 May;41(5):253-8. doi: 10.4070/kcj.2011.41.5.253. Epub 2011 May 31.


Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL.

Marchesi M, Parolini C, Caligari S, Gilio D, Manzini S, Busnelli M, Cinquanta P, Camera M, Brambilla M, Sirtori CR, Chiesa G.

Br J Pharmacol. 2011 Nov;164(5):1460-8. doi: 10.1111/j.1476-5381.2011.01429.x.


Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.

Jia L, Betters JL, Yu L.

Annu Rev Physiol. 2011;73:239-59. doi: 10.1146/annurev-physiol-012110-142233. Review.


Dietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1.

Jia L, Ma Y, Liu G, Yu L.

J Lipid Res. 2010 Oct;51(10):3024-33. doi: 10.1194/jlr.M008599. Epub 2010 Jul 2.


Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.

Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ.

J Lipid Res. 2010 Jun;51(6):1546-53. doi: 10.1194/jlr.P002816. Epub 2009 Dec 2.


Impact of ezetimibe on atherosclerosis: is the jury still out?

Al Badarin FJ, Kullo IJ, Kopecky SL, Thomas RJ.

Mayo Clin Proc. 2009 Apr;84(4):353-61. doi: 10.1016/S0025-6196(11)60545-4. Review.


Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.

Barter P, Ginsberg HN.

Am J Cardiol. 2008 Oct 15;102(8):1040-5. doi: 10.1016/j.amjcard.2008.05.056. Epub 2008 Jul 31. Review. Erratum in: Am J Cardiol. 2009 Feb 1;103(3):435.


Clinical efficacy and safety of statins in managing cardiovascular risk.

Kapur NK, Musunuru K.

Vasc Health Risk Manag. 2008;4(2):341-53. Review.


Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

McTaggart F, Jones P.

Cardiovasc Drugs Ther. 2008 Aug;22(4):321-38. doi: 10.1007/s10557-008-6113-z. Epub 2008 Jun 14. Review.


Thyroid mimetic as an option for lowering low-density lipoprotein.

Grundy SM.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):409-10. doi: 10.1073/pnas.0705959104. Epub 2008 Jan 10. No abstract available.


Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.

Bays H, Jones PH.

Vasc Health Risk Manag. 2007;3(5):733-42. Review.


Optimal lipid modification: the rationale for combination therapy.

Backes JM, Gibson CA, Howard PA.

Vasc Health Risk Manag. 2005;1(4):317-31. Review.

Supplemental Content

Support Center